All In MedTech

Device Trial Radar · NCT04644731

Ultrafiltration Therapy Registry Using Aquadex (ULTRA-Peds)

ULTRA-Peds: A Multicenter Data Registry for Outcomes for Pediatric Volume Overload

Last checked: Nov 20, 2026Latest source record: Feb 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

97

Actual

Start

Apr 9, 2021

Primary completion

Sep 13, 2023

Study completion Sep 13, 2023

Sponsor

Lead sponsor
Nuwellis, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
AKI Critical Care Research Foundation
First posted
Nov 25, 2020

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ULTRA-Peds registry will employ a multi-center, single-arm, open-label, observational design to capture baseline, procedural and follow-up data on pediatric patients that have been treated (i.e., retrospective data from treatment at the time of registry approval by the IRB) or are scheduled to be treated (i.e., prospective data for on-label treatment after registry approval by the IRB) with Aquadex therapy according to local standard of care practices and decisions. All prospective data will be from on-label Aquadex treatment of pediatric patients weighing 20 kilograms or more. No data from prospective off-label treatment (i.e., Aquadex treatment with other adjunctive or conjunctive therapies for pediatric patients who may weigh less than 20kg) will be included in the registry. An estimated 10 sites in the United States who have received training in extracorporeal therapy and the Aquadex™ system will enroll a minimum of 500 patients.

Conditions

  • Fluid Overload

Interventions

  • Aquadex™ SystemDevice

    Ultrafiltration for fluid removal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment SurvivalTime frame: Through completion of a treatment course, up to 3 months
  2. Survival at ICU dischargeTime frame: Through completion of a treatment course in the ICU, up to 1 month
  3. Change in Kidney FunctionTime frame: Change eGFR and renal labs from initiation to completion of treatment, up to 3 months

6 more outcomes with a free account

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Children's of Alabama Hospital

    Birmingham, Alabama

  • Lucile Packard Children's Hospital Stanford

    Palo Alto, California

  • Joe DiMaggio Children's Hospital

    Hollywood, Florida

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.